Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- PAD-2 PADI-2 protein arginine deiminase PAD amidino-transferase b/g-actin anti-body immunochemical detection antisera antiserum antibodies peptidyl auto-antibodies auto-antibody RA MS ?-actin ?-actin b-action g-actin H-3
- Product Overview:
Protein Arginine Deiminases (PADs) are guanidino-modifying enzymes belonging to the amidinotransferase superfamily and are designated PAD1-4 and PAD6. PAD enzymes catalyze the conversion of specific arginine residues to citrulline in a calcium-dependent manner. All enzymes are cytosolic except for PAD4 which is localized in the nucleus.{18141} PAD2 is the most widely expressed member and also the most conserved across mammalian species, implying it is the ancestral homologue of the PADs.{19489} Overexpression of PAD2 results in myelin loss in a transgenic model, potentially linking PAD2 activity to multiple sclerosis.{30727} It has also been shown to modify vimentin and ?/?-actin, potentially aggravating the autoantigen response in rheumatoid arthritis.{30728,30130} PAD2 may also play a role in transcriptional regulation, as it has been shown capable of citrullinating histones, particularly H3 during mammalian reproductive cycles, when it is transcriptionally activated in the nucleus.{30729} The predicted molecular weight of PAD2 is 75.6 kDa and Cayman’s PAD2 Monoclonal Antibody (Clone 9F7) detects a band at 75 kDa by western blot.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.